Serum thrombomodulin - A reliable marker of disease activity in systemic lupus erythematosus (SLE): Advantage over established serological parameters to indicate disease activity

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 189-195

  Boehme, M W J ^a,d   Raeth, U ^a   Galle, P R ^a,b   Stremmel, W ^a   Scherbaum, W A ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Hosp of Int Med and Rheumatology   (Germany)

Author keywords

Disease activity; Systemic lupus erythematosus; Thrombomodulin endothelial cell damage

Indexed keywords

COMPLEMENT COMPONENT C3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SOLUBILITY; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE-1; VASCULITIS;

EID: 0033956416     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01107.x     Document Type: Article

References (51)

1. 1 Koffler D. Immunpathogenesis of systemic lupus erythematosus. Ann Rev Med 1974; 25:149-64.
2. 2 Esdaile JM, Abrahamowicz M, Joseph L et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39:370-8.
3. 3 Spronk PE, Limburg PC, Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995; 4:86-94.
4. 4 Manzi S, Rairie JE, Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39:1178-88.
5. 5 Swaak AJG, Groenwald J, Bronsveld W. Predicitive value of complement profiles and anti-ds-DNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45:359-66.
6. 6 Gabay C, Roux-Lombard P, de-Moerloose P et al. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20:815-21.
7. 7 TerBorg EJ, Horst G, Hummel EJ et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33:634-43.
8. 8 TerBorg EJ, Horst G, Limburg PC et al. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-ds-DNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990; 82:21-6.
9. 9 Linker-Israeli M, Bakke AC, Kitridou RC et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130:2651-5.
10. 10 Kling E, Bieg S, Boehme M et al. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. Clin Invest 1993; 71:299-304.
11. 11 Spronk PE, ter-Borg EJ, Limburg PC et al. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity. Clin Exp Immunol 1992; 90:106-10.
12. 12 Houssiau FA, Lefebvre C, Vanden-Berghe M et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4:393-5.
13. 13 Garcia-Cozar FJ, Molina IJ, Cuadrado MJ et al. Defective B7 expression on antigen-presenting cells underlying T-cell activation abnormalities in systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 1996; 104:72-9.
14. 14 Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993; 36:519-27.
15. 15 Spronk PE, Bootsma H, Huitema MG et al. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97:439-44.
16. 16 Carson CW, Beall LD, Hunder GG et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20:809-14.
17. 17 Takaya M, Ichikawa Y, Kobayashi N et al. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1991; 9:495-9.
18. 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus. J Rheumatol 1992; 19:1704-9.
19. 19 Boehme MWJ, Nawroth PP, Kling E et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994; 37:572-7.
20. 20 Karmochkine M, Boffa MC, Piette JC et al. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood 1992; 79:837-8.
21. 21 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78:2249-52.
22. 22 Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75:329-36.
23. 23 Ishii H, Yama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemostas 1991; 65:618-23.
24. 24 Sawada K, Yamamoto H, Yago H et al. A simple assay to detect endothelial cell injury; measurement of released thrombomodulin from cells. Exp Mol Pathol 1992; 57:116-23.
25. 25 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
26. 26 Liang MH, Socher SA, Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32:1107-18.
27. 27 Hergesell O, Andrassy K, Geberth S et al. Plasma thrombomodulin levels are dependent on renal function. Thromb Res 1993; 72:455-8.
28. 28 Boehme MWJ, Kataaha PK, Holborow EJ. Autoantibodies to intermediate filaments in sera of patients with Schistosoma mansoni infection. Clin Exp Immunol 1989; 77:230-3.
29. 29 Duncan DB. Multiple range and multiple F-tests. Biometrics 1955; 11:1-42.
30. 30 Landis JR, Kock GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-74.
31. 31 Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus. A discordance between clinical and serologic features. Am J Med 1979; 66:210-5.
32. 32 D'Cruz DP, Houssiau FA, Ramirez G et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991; 85:254-61.
33. 33 Blaschek MA, Boehme M, Jouquan J et al. Relation of antivimentin antibodies to anti-cardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1988; 47:708-16.
34. 34 Richaud-Platin Y, Alcover-Varela J, Liorente L. High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995; 47:267-72.
35. 35 Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11:767-804.
36. 36 Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14:506-12.
37. 37 Gearing AJ, Hemingway I, Pigott R et al. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann NY Acad Sci 1992; 667:324-31.
38. 38 Pigott R, Dillon LP, Hemingway IH et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187:584-9.
39. 39 Hashimoto Y, Nakano K, Yoshinoya S et al. Endothelial cell destruction by polymorphonuclear leukocytes incubated with sera from patients with systemic lupus erythematosus (SLE). Scand J Rheumatol 1992; 21:209-14.
40. 40 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73:159-65.
41. 41 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77:542-50.
42. 42 Boehme MWJ, Deng Y, Raeth U et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunol 1996; 87:134-40.
43. 43 Boehme MWJ, Autschbach F, Zuna I et al. Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterol 1997; 113:107-17.
44. 44 Boehme MWJ, Schmitt WH, Youinou P et al. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101:387-94.
45. 45 Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996; 75:892-8.
46. 46 Tanaka A, Ishii H, Hiraishi S et al. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37:269-72.
47. 47 Takakuwa T, Endo S, Nakae H et al. Plasma levels of TNF-alpha, endothelin-1 and thrombomodulin in patients with sepsis. Pharmacol 1994; 84:261-9.
48. 48 Endo S, Inada K, Nakae H et al. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis. Res Com Mol Pathol Pharmacol 1995; 90:277-88.
49. 49 Boehme MWJ, Werle E, Kommerell B et al. Serum levels of adhesion molecules and thrombomodulin as indicator of vascular injury in severe Plasmodium falciparum malaria. Clin Invest 1994; 72:598-603.
50. 50 Hemmer CJ, Bierhaus A, Riedesel J et al. Elevated thrombomodulin plasma levels as a result of endothelial involvement in Plasmodium falciparum malaria. Thromb Haemost 1994; 72:457-64.
51. 51 Asakura H, Jokaji H, Saito M et al. Plasma levels of soluble thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure. Am J Hematol 1991; 38:281-7.